$5.03
-0.14-2.71%
At close: Sep 28, 5:00 PM EST
$5.25
0.081.55%
Pre-Market: 8:21 AM EST
Vanda Pharmaceuticals Inc
VNDANASDAQ
Vanda Pharmaceuticals Earnings & Forecasts
Vanda Pharmaceuticals (VNDA) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Vanda Pharmaceuticals Guidance
Vanda Pharmaceuticals (VNDA) last issued guidance on August 5, 2026 for fiscal year 2026. The company guided revenue in the range of $240M - $290M for the period.
Compared to prior guidance, Vanda Pharmaceuticals maintained its revenue forecast from a prior range of $240M - $290M.
Vanda Pharmaceuticals has issued 10 guidance updates between November 2, 2022 and August 5, 2026. During this period, the company raised its outlook 4 times and lowered it 2 times, providing investors with insight into management's evolving expectations.
Recent Earnings Results
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.57 | $-0.66 | $-1.67 | $-0.40 |
| Actual | $-1.04 | $-0.82 | $-2.39 | $-0.38 |
| Surprise | -82.5% | -24.2% | -43.1% | +5.00% |
| Revenue | ||||
| Estimate | $62.1M | $54.7M | $59.1M | $59.2M |
| Actual | $50.5M | $51.7M | $57.2M | $56.3M |
| Surprise | -18.6% | -5.52% | -3.20% | -5.03% |
Analyst Estimates — Forward PeriodsSource: Wall Street consensus
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.69 | $-0.48 | $-0.41 | $-0.24 |
| Revenue | ||||
| Consensus | $68.2M | $76.9M | — | — |
